ArticleCell death & disease2021

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy.

Violetta Ritter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.